Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Cerny

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Molecular Pharmaceutics|May 3, 2023
Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting PolypeptidesChristine C Orozco, Mikko Neuvonen, Yi-An Bi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 7, 2024
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, et al.
Clinical Pharmacology and Therapeutics|September 22, 2020
Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 BiomarkersMikko Neuvonen, Päivi Hirvensalo, Aleksi Tornio, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2025
Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosingSteven M Weldon, Derek A Cogan, Matthew A Cerny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2022
<b>Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease</b>Yan Weng, Kari R Fonseca, Yi-An Bi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2017
Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting PolypeptidesRhishikesh Thakare, Hongying Gao, Rachel E Kosa, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2014
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanismRyan M Fryer, Khing Jow Ng, Suzanne G Nodop Mazurek, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activityKenneth Meyers, Derek A Cogan, Jennifer Burke, et al.
Pharmaceutical Research|November 4, 2024
The Current State of Biotransformation Science - Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future TrendsJohn P Savaryn, Kevin Coe, Matthew A Cerny, et al.
Journal of Medicinal Chemistry|November 19, 2024
Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948Kevin J Filipski, Luis A Martinez-Alsina, Matthew R Reese, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Molecular Pharmaceutics|May 3, 2023
Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting PolypeptidesChristine C Orozco, Mikko Neuvonen, Yi-An Bi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 7, 2024
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, et al.
Clinical Pharmacology and Therapeutics|September 22, 2020
Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 BiomarkersMikko Neuvonen, Päivi Hirvensalo, Aleksi Tornio, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2025
Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosingSteven M Weldon, Derek A Cogan, Matthew A Cerny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2022
<b>Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease</b>Yan Weng, Kari R Fonseca, Yi-An Bi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2017
Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting PolypeptidesRhishikesh Thakare, Hongying Gao, Rachel E Kosa, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2014
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanismRyan M Fryer, Khing Jow Ng, Suzanne G Nodop Mazurek, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activityKenneth Meyers, Derek A Cogan, Jennifer Burke, et al.
Pharmaceutical Research|November 4, 2024
The Current State of Biotransformation Science - Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future TrendsJohn P Savaryn, Kevin Coe, Matthew A Cerny, et al.
Journal of Medicinal Chemistry|November 19, 2024
Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948Kevin J Filipski, Luis A Martinez-Alsina, Matthew R Reese, et al.
Pageof 4